Comparative Pharmacology
Head-to-head clinical analysis: GYNAZOLE 1 versus MYCELEX 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNAZOLE 1 versus MYCELEX 7.
GYNAZOLE-1 vs MYCELEX-7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butoconazole nitrate, an imidazole antifungal agent, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing fungal cell membrane permeability.
Clotrimazole, an azole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
One 100 mg vaginal ovule inserted intravaginally as a single dose.
Clotrimazole 100 mg vaginal tablet inserted intravaginally once daily at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 days after intravaginal administration, reflecting slow absorption from the vaginal mucosa and prolonged retention in tissues.
The systemic half-life of clotrimazole following vaginal administration is approximately 0.5–1 hour due to rapid metabolism and elimination. This short half-life reflects minimal systemic absorption (3–10%).
Primarily as unchanged drug in feces via biliary elimination; <1% excreted renally as metabolites.
Primarily via feces as unchanged drug (approx. 50%) and metabolites. Renal excretion of unchanged drug is minimal (<1%) as the drug is poorly absorbed from the vagina. Biliary excretion contributes to fecal elimination.
Category C
Category C
Azole Antifungal
Azole Antifungal